Details:
CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.
Lead Product(s): Foslinanib,Sorafenib
Therapeutic Area: Oncology Product Name: CVM-1118
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: TaiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 27, 2022
Details:
Under the agreement, Ainos and Merdury will evaluate the feasibility of Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's Veldona (interferon alfa) drug candidate for treatment of oral warts in HIV-seropositive patients.
Lead Product(s): Interferon Alfa
Therapeutic Area: Oncology Product Name: Veldona
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Ainos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 14, 2023
Details:
Antroquinonol outperformed the other listing drugs for the treatment of relapsed acute myeloid leukemia in its Phase 2 clinical trial. 80% of patients showed that their blasts count were less than 5%. 90% of patients did not need blood transfusion during trial period.
Lead Product(s): Antroquinonol
Therapeutic Area: Oncology Product Name: Hocena
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2020